A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid

Autor Santos, V.n. Autor UNIFESP Google Scholar
Lanzoni, Valeria Pereira Autor UNIFESP Google Scholar
Szejnfeld, Jacob Autor UNIFESP Google Scholar
Shigueoka, David Carlos Autor UNIFESP Google Scholar
Parise, Edison Roberto Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo In order to determine the effect of ursodeoxycholic acid on nonalcoholic fatty liver disease, 30 patients with body mass indices higher than 25, serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma-glutamyltransferase (gamma-GT) at least more than 1.5 times the upper limit of normality, and hepatic steatosis demonstrated by ultrasonography were randomized into two groups of 15 patients to receive placebo or 10 mg kg-1 day-1 ursodeoxycholic acid for three months. Abdominal computed tomography was performed to quantify hepatic fat content, which was significantly correlated with histological grading of steatosis (r s = -0.83, P < 0.01). Patient body mass index remained stable for both groups throughout the study, but a significant reduction in mean (± SEM) serum levels of ALT, AST and gamma-GT was observed only in the treated group (ALT = 81.2 ± 9.7, 44.8 ± 7.7, 48.1 ± 7.7 and 52.2 ± 6.3 IU/l at the beginning and after the first, second and third months, respectively, N = 14, P < 0.05). For the placebo group ALT values were 66.4 ± 9.8, 54.5 ± 7, 60 ± 7.6 and 43.7 ± 5 IU/l, respectively. No alterations in hepatic lipid content were observed in these patients by computed tomography examination (50.2 ± 4.2 Hounsfield units (HU) at the beginning versus 51.1 ± 4.1 HU at the third month). These results show that ursodeoxycholic acid is able to reduce serum levels of hepatic enzymes in patients with nonalcoholic fatty liver disease, but this effect is not related to modifications in liver fat content.
Assunto Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Fatty liver
Ursodeoxycholic acid
Idioma Inglês
Data 2003-06-01
Publicado em Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 36, n. 6, p. 723-729, 2003.
ISSN 0100-879X (Sherpa/Romeo, fator de impacto)
Editor Associação Brasileira de Divulgação Científica
Extensão 723-729
Fonte http://dx.doi.org/10.1590/S0100-879X2003000600007
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000183866400007
SciELO S0100-879X2003000600007 (estatísticas na SciELO)
URI http://repositorio.unifesp.br/handle/11600/1764

Mostrar registro completo

Arquivos deste item

Nome: S0100-879X2003000600007.pdf
Tamanho: 526.9Kb
Formato: PDF

Este item aparece na(s) seguinte(s) coleção(s)